Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus

Clin Infect Dis. 2010 Jun 1;50(11):1493-6. doi: 10.1086/652655.

Abstract

Immunosuppressed patients receiving oseltamivir for 2009 novel H1N1 influenza A infection may develop drug resistance, leading to treatment failure. Intravenous zanamivir was administered on a compassionate-use basis to a profoundly immunosuppressed pediatric patient with severe oseltamivir-resistant novel H1N1 pneumonia. The regimen was well tolerated and was associated with a decrease in viral burden.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / pharmacology*
  • Compassionate Use Trials
  • Critical Illness
  • Drug Resistance, Viral*
  • Female
  • Humans
  • Immunocompromised Host
  • Infant
  • Influenza A Virus, H1N1 Subtype / drug effects
  • Influenza A Virus, H1N1 Subtype / isolation & purification*
  • Influenza, Human / drug therapy*
  • Influenza, Human / virology
  • Injections, Intravenous
  • Oseltamivir / pharmacology*
  • Treatment Outcome
  • Viral Load
  • Zanamivir / administration & dosage*
  • Zanamivir / adverse effects

Substances

  • Antiviral Agents
  • Oseltamivir
  • Zanamivir